Monte Carlo dosimetric analyses on the use of 90Y-IsoPet intratumoral therapy in canine subjects
Mislav Bobić, Carlos Huesa-Berral, Jack F Terry, Louis Kunz, Jan Schuemann, Darrell R Fisher, Charles A Maitz, Alejandro Bertolet
Abstract
Purpose: To investigate different dosimetric aspects of 90Y-IsoPet™ intratumoral therapy in canine soft tissue sarcomas, model the spatial spread of the gel post-injection, evaluate absorbed dose to clinical target volumes, and assess dose distributions and treatment efficacy.
Approach: Six canine cases treated with 90Y-IsoPet™ for soft tissue sarcoma at the Veterinary Health Center, University of Missouri are analyzed in this retrospective study. The dogs received intratumoral IsoPet™ injections, following a grid pattern to achieve a near-uniform dose distribution in the clinical target volume.
Radiation Safety for Yttrium-90-polymer Composites (RadioGel®) in Therapy of Solid Tumors
Darrell R. Fisher
Abstract
Yttrium-90 (90Y)-polymer composite (RadioGel®) is a new cancer therapeutic agent for treating solid tumors by direct interstitial injection. The 90Y-composite comprises insoluble, microscopic yttrium-phosphate particles carried by a sterile, injectable water-polymer (hydrogel) solution that can be placed directly by needle injection into solid tumors. The yttrium-90-RadioGel™ agent was designed to provide a safe, effective, localized, high-dose beta radiation for treating solid tumors. The properties of 90Y-RadioGel® also make it a relatively safe agent for health care personnel who prepare, handle, and administer the material. The purpose of this work was to demonstrate and characterize radiation safety of the injectable 90Y-RadioGel® therapeutic agent.
Direct Interstitial Treatment of Solid Tumors Using an Injectable Yttrium-90-Polymer Composite
Darrell R. Fisher, Janean Fidel, and Charles A. Maitz
Abstract
Purpose: Yttrium-90 (90Y)-polymer composite (RadioGel®) may be administered directly into cancerous tissues to deliver highly localized beta radiation for therapy. In a dose-escalation study, the authors investigated the feasibility of treating feline and canine soft-tissue sarcomas as a model for nonresectable solid tumors in humans to gain clinical experience and to identify optimal methods for placing the composite uniformly within target tumor tissue.